Morgan Stanley analyst Patrick Wood maintained a Buy rating on Boston Scientific (BSX – Research Report) today and set a price target of ...

Feb 5 (Reuters) - Medical device maker Boston Scientific (BSX.N), opens new tab forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.

Truist Financial analyst Richard Newitter maintained a Buy rating on Boston Scientific (BSX – Research Report) today and set a price target of $120.00. The company’s shares closed yesterday at ...

Commanding a market cap of $150.9 billion, Boston Scientific Corporation (BSX) is a global medical device manufacturer that develops, manufactures, and markets a broad range of innovative products.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

But there’s a powerful fundamental story happening with Boston Scientific. Also, EPS is estimated to ramp higher this year by +13.8%. Now it makes sense why the stock has been powering to new ...

I’m still a believer in the story at Boston Scientific, but the valuation situation remains challenging. I do think there’s a credible chance of BSX generating 10% long-term revenue growth and ...

Boston Scientific Corporation today announced it has entered into a definitive agreement to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy (IVL) advanced laser-based ...

Bringing Pittcon to Boston represents a perfect alignment of mission and location,” said Heather Juzwa, President of Pittcon 2025. “The city’s concentration of scientific talent, from ...